PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW146137View Pathway |
drug action
Selenomethionine Se-75 Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:29 Last Updated: October 07, 2023 at 17:29 |
PW128107View Pathway |
drug action
Selexipag Action PathwayHomo sapiens
Selexipag is a non-prostanoid prostacyclin receptor agonist, also known as Uptravi typically used to treat pulmonary arterial hypertension. Selexipag is a selective prostacyclin receptor agonist, it is administered orally and is metabolized by carboylesterase1 into its active metabolite (ACT-333679). The metabolite has a high selectivity for prostacyclin receptor that activates it and subsequent G coupled protein, Gs, that increases cAMP levels. Increased cAMP levels leads to inhibited platelet aggregation and activation.
|
Creator: Selena Created On: July 18, 2023 at 12:12 Last Updated: July 18, 2023 at 12:12 |
PW146368View Pathway |
drug action
Selexipag Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 18:02 Last Updated: October 07, 2023 at 18:02 |
PW132448View Pathway |
Selinexor Drug MetabolismHomo sapiens
Selinexor is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Selinexor passes through the liver and is then excreted from the body mainly through the kidney.
|
Creator: Ray Kruger Created On: September 21, 2023 at 21:50 Last Updated: September 21, 2023 at 21:50 |
PW146472View Pathway |
drug action
Selinexor Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 18:17 Last Updated: October 07, 2023 at 18:17 |
PW146936View Pathway |
drug action
Selpercatinib Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 19:23 Last Updated: October 07, 2023 at 19:23 |
PW146426View Pathway |
drug action
Selumetinib Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 18:10 Last Updated: October 07, 2023 at 18:10 |
PW146701View Pathway |
drug action
Semaglutide Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 18:50 Last Updated: October 07, 2023 at 18:50 |
PW121812View Pathway |
disease
Sepiapterin Reductase DeficiencyMus musculus
Sepiapterin reductase deficiency results from a metabolic disorder; namely, the underproduction of Sepiapterin. The cause of this underproduction is an autosomal recessive genetic mutation in the SPR gene. This gene is responsible for Sepiapterin production, and naturally, when the gene malfunctions the production of this metabolite is altered leading to a range of effects on the body. In this case, some symptoms of Sepiapterin Deficiency are: motor and speech delay, axial hypotonia, dystonia, weakenss microcephaly, dysarthria, autonomic dysfunction, oculogyric crises, drowsiness, among others.
|
Creator: Ana Marcu Created On: September 10, 2018 at 15:49 Last Updated: September 10, 2018 at 15:49 |
PW000467View Pathway |
disease
Sepiapterin Reductase DeficiencyHomo sapiens
Sepiapterin reductase deficiency results from a metabolic disorder; namely, the underproduction of Sepiapterin. The cause of this underproduction is an autosomal recessive genetic mutation in the SPR gene. This gene is responsible for Sepiapterin production, and naturally, when the gene malfunctions the production of this metabolite is altered leading to a range of effects on the body. In this case, some symptoms of Sepiapterin Deficiency are: motor and speech delay, axial hypotonia, dystonia, weakenss microcephaly, dysarthria, autonomic dysfunction, oculogyric crises, drowsiness, among others.
|
Creator: WishartLab Created On: August 29, 2013 at 08:33 Last Updated: August 29, 2013 at 08:33 |